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Abstract 
Increasing cell survival in stem cell therapy is an important challenge for the field of regenerative 
medicine. Here, we report theranostic mesoporous silica nanoparticles that can increase cell 
survival through both diagnostic and therapeutic approaches. First, the nanoparticle offers ul-
trasound and MRI signal to guide implantation into the peri-infarct zone and away from the most 
necrotic tissue. Second, the nanoparticle serves as a slow release reservoir of insulin-like growth 
factor (IGF)—a protein shown to increase cell survival. Mesenchymal stem cells labeled with these 
nanoparticles had detection limits near 9000 cells with no cytotoxicity at the 250 µg/mL con-
centration required for labeling. We also studied the degradation of the nanoparticles and showed 
that they clear from cells in approximately 3 weeks. The presence of IGF increased cell survival up 
to 40% (p<0.05) versus unlabeled cells under in vitro serum-free culture conditions. 
Key words: Stem Cell Therapy, Theranostic, Pro-survival, Mesoporous Silica Nanoparticles. 
Introduction 
Cardiac stem cell therapy has shown encourag-
ing initial results in treating heart disease [1-3], yet is 
plagued by poor long-term efficacy because of rapid 
cell death after implantation [2, 4]. This is attributed to 
two fundamental challenges—1) ischemia and in-
flammation in the treated area [4] and 2) mis-injection 
or implant into highly fibrotic tissue [5, 6]. Because of 
these barriers, less than 2% of implanted stem cells 
remain viable after 4-8 weeks [6] with cells 
mis-injected in 50% of patients [7]. To combat 
ischemia and inflammation, pro-survival cocktails 
have been shown to increase stem cell proliferation[8], 
yet this work is limited by the short half-lives and 
poor bioavailability of these agents. 
Echocardiography can be used to avoid implantation 
into fibrotic tissue, but cellular imaging for surgical 
guidance is limited by the lack of available contrast 
agents. Here we propose a mesoporous silica 
nanoparticle that solves both of these major limita-
tions through a combined therapeutic and diagnos-
tic—“theranostic”—approach.  
Ultrasound is a promising tool for real-time im-
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aging of cell delivery because of its high spa-
tial/temporal resolution and its many centimeters of 
imaging depth. Ultrasound is already routinely used 
in echocardiography and images the catheter used to 
deliver stem cells. Contrast agents for ultrasound 
molecular imaging are primarily composed of per-
fluorocarbons—both gaseous micrometer-sized bub-
bles [9-12] and liquid droplets [13]. However, these 
probes are limited by the micron size of the bubble as 
well as its short life time (<30 minutes)—challenges 
that can be overcome with nanotechnology [14, 15].  
Recently, we [16] and others [17-21] have re-
ported that silica-based nanoparticles offer contrast 
for ultrasound imaging. Just as the interface between 
tissue and the gaseous microbubbles offer an imped-
ance mismatch, so too does the interface between tis-
sue and the rigid silica particles. These nanoparticles 
can be used for real time stem cell imaging and quan-
titation with ultrasound to avoid delivery into fibrotic 
tissue [16, 22]. The nanoparticles are loaded inside of 
cells rather than co-injection with microbubbles [5, 23] 
or surface-bound microbubbles [12, 24]. This ensures 
that the nanoparticle reporter corresponds to the cell 
of interest. Our previous work used Stöber silica na-
noparticles, but these probes have a very long bio-
degradation time due to their dense silicate network 
and low dissociation constant of silica and cannot 
deliver pro-survival agents to increase the survival of 
stem cells.  
Thus, this work transitions to mesoporous silica 
nanoparticles (MSNs)[25-30], which offer high surface 
area (~1000 m2/g)[31] due to micelle-templated pores 
with tunable sizes and charges through a variety of 
silane chemistry techniques [31]. While many groups 
have used MSNs for drug delivery related to cancer 
[32], we hypothesized that they could also be used to 
deliver pro-survival agents to stem cells while also 
serving as a contrast agent. A second goal was to use 
the high surface area to facilitate biodegradation and 
clearance from living systems.  
Here, we report the construction and validation 
of mesoporous silica nanoparticles as a theranostic 
tool for stem cell therapy. We used insulin-like 
growth factor (IGF) as a model pro-survival agent 
because of its established role in cardiac stem cell 
therapy [33, 34]. This report presents concurrent ul-
trasound/magnetic resonance imaging as well as 
drug delivery with MSNs. The ultrasound is useful 
for image-guided delivery and quantitation, the MRI 
offers higher resolution follow-up studies, and the 
drug delivery prevents stem cell death. This approach 
may offer important advantages for cardiac stem cell 
therapy as well as abdominal applications of regen-
erative medicine amenable to ultrasound imaging.  
Materials and Methods 
Reagents. Mesoporous silica nanoparticles were 
purchased from Sigma with a nominal diameter of 200 
nm and a 4 nm pore size (p/n 748161). Aminopro-
pyl-trimethoxysilane (APTES), gadolinium chloride, 
fluorescein isothiocyanate were also purchased from 
Sigma. A N-hydroxysuccinimide NHS derivative of 
1,4,7,10-tetraaza-cyclododecane-1,4,7,10-tetraacetic 
acid (DOTA) was purchased from Macrocyclics.  
Nanoparticle Synthesis. An amino-silane con-
jugate of fluorescein was first made by adding 5.25 
mg fluorescein isothiocyanate to 73 μL of 
3-aminopropyltrimethoxysilane (APTES) in 1 mL 
ethanol total volume with overnight rotation. Next, 
MSNs (1 g) were dissolved in 100 mL of ethanol and 
bath sonicated for 20 minutes to completely disperse 
any aggregates. Then, 3 mL of APTES was added and 
the solution gently refluxed for 90 minutes with stir-
ring. The solution was further stirred overnight at 
room temperature, and the next day 500 µL of the 
fluorescein product was added for an additional hour 
of stirring. The product was washed thrice with eth-
anol, twice with a 1:1 mixture of ethanol/PBS, and 
twice with PBS. Then 50 mg of NHS-DOTA was 
added and the solution stirred at room temperature 
for 1 hour and then washed thrice with PBS. Then, 300 
mg GdCl3 was added and the solution was incubated 
for 2 hours in a 50oC water bath. The final product 
was washed again with water and dialyzed overnight 
versus constantly regenerated water.  
Nanoparticle Characterization. Dynamic light 
scattering was performed with a Malvern Zetasizer. 
All transmission electron microscopy (TEM) and en-
ergy-dispersive x-ray spectroscopy (EDS) was per-
formed with a Tecnai G2 X-Twin (FEI Co.) instrument 
operating at 200 kV. MSNs were dissolved in 10 M 
NaOH with sonication for 1 hour, then neutralized 
and diluted with 5% nitric acid for Inductively Cou-
pled Plasma-Optical Emission Spectroscopy (ICP) 
analysis on an ICAP 6300 system (Thermo Scientific) 
using 1 and 10 ppm solutions of Gd and Si as stand-
ards (Fluka). All absorbance and fluorescence meas-
urements used a plate reader from Biotek.  
Degradation Experiments. We used a modified 
open system dissolution apparatus to study the decay 
of MSNs [35]. This home built system consisted of a 
peristaltic pump moving 0.1X PBS at 0.5 mL/min into 
a 300 mL sintered glass funnel serviced by overhead 
stirring. After equilibration and collection of some 
initial fractions to measure background silica content, 
22 mg of MSNs were added and fractions then col-
lected daily. The “eluent” drained into a 4 L plastic 
beaker and fractions were collected periodically for 
elemental analysis. Samples (200 µL) from the reten-
tate were periodically removed, centrifuged, and im-
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aged with TEM.  
To study degradation inside cells, MSCs were 
labeled with MSNs and then re-plated at 5000 
cells/cm2 and grown for 1, 2, or 3 weeks. Aliquots of 
media were removed periodically for ICP analysis. At 
the end of the 1, 2, or 3 weeks cells were detached 
from the culture flask and prepared for TEM. This 
sample preparation has been described previously 
[22]. Briefly, the samples were stained en bloc with 
osmium tetroxide and uranyl acetate. Dehydrated 
samples were sectioned and placed on copper grids 
(Ted Pella).  
Ultrasound and Magnetic Resonance Imaging. 
We used a Vevo2100 system from Visualsonics for the 
ultrasound imaging at 40 MHz (M550 transducer) and 
16 MHz (M250 transducer). We used imaging param-
eters determined empirically including 100% power, 
20 dB gain, 65 dB dynamic range, and 21 and 40 MHz 
center frequencies. The sample was 1 cm from the 
transducer. MRI utilized a 1 T magnet from Bruker 
with auto-shimming. The pulse sequence was T1 
FLASH at 3.5 cm field-of-view, an echo time of 6.3 ms, 
repetition time of 120 ms, flip angle of 80o, a 256 x 256 
matrix (13.7 µm/pixel), 8 excitations, auto gain cali-
bration, and vertical frequency directions. Five 1.25 
mm slices were collected with 1.5 mm between slices.  
Cell Culture, Labeling, and Proliferation As-
says. Human bone marrow mesenchymal stem cells 
(MSCs) were acquired from Lonza (p/n PT-2501) and 
seeded at 5000 cells/cm2 in media from Lonza 
(PT-3001). For survival studies, we used the same 
media, but without the BSA and L-glutamine that 
were present in complete media. Cell labeling was 
done without transfection agents and introduced 
MSNs in fresh cell culture media. The cells were in-
cubated under standard conditions and then washed 
thrice to ensure only the MSNs endocytosed by cells 
were remaining in the plate. Cells were detached with 
TrypLE Express (Life Technologies). For proliferation 
assays, labeled (250 µg/mL) and unlabeled cells were 
plated at 1000 cell/well in each well of a 96 well plate. 
The cell number was measured with a 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe
nyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay. 
Here, 20 μL of MTS solution was added to each well 
and the plate incubated for 3 hours followed by ab-
sorbance measurement at 490 nm. Confocal micros-
copy used a Leica confocal microscope (TCS SP5) with 
a 20x APO objective (p/n 506147) seated on a Vir-
braplane air table. For z-stacking experiments, 20 
slices were collected over ~ 50 µm. Videos were made 
by compiling the individual TIFF files into an .avi file. 
Epifluorescence microscopy used an Evos microscope 
(Life Technologies) and 2-(4-amidinophenyl)-1H 
-indole-6-carboxamidine (DAPI) for nuclear staining.  
Toxicity Assays. In addition to the MTS assay, 
we also used the resazurin (Alamar Blue; Invitrogen) 
assay. Cells with increasing amount of MSNs were 
treated with 100 μL of reszurin and allowed to incu-
bate under standard conditions for 3 hours followed 
by fluorescence measurements at 570 nm excitation 
and 590 nm emissions. The EthD-III assay (Biotium) 
also used plated cells and tested for disrupted cell 
membranes in necrotic or apoptotic cells. After 4 
hours of treatment with MSNs, MSCs were labeled 
with 4 µM EthD-III, and then the fluorescence signal 
at 530 nm excitation and 620 nm emissions were 
measured. Metabolic activity was also measured with 
an ATP/luciferase assay (Promega) according the 
manufacturer’s instructions. Green channel biolumi-
nescence was collected for 1 minute 20 minutes after 
adding the luciferin and luciferase. For all toxicity 
controls, we used a positive control of 15 μL of 2 
mg/mL cetyltrimethylammonium bromide (CTAB) in 
PBS that was added concurrently with the MSNs. 
Reactive oxygen species (ROS) were measured with 
2′,7′-dichlorodihydrofluorescein diacetate (DCFH- 
DA) in Hank’s buffer. This reagent was added to the 
cells at 25 µM and incubated for 1 hour followed by 
washing. Then, increasing concentrations of MSNs 
were added as well as 10% hydrogen peroxide (posi-
tive control). The cells were incubated for another 
hour followed by fluorescence measurements with 
standard fluorescein optical settings.  
Pro-Survival Agents. The MSNs were loaded 
with drug as described previously [26, 27]. Briefly, 
MSNs were dissolved in PBS at 2 mg/mL and then 
recombinant IGF-1 (Peprotech) to 23 µg/mL working 
concentration was added with rotation in the cold 
room. Four hours later, the material was washed with 
PBS three times. To monitor the loading, we used a 
bicinchoninic acid (BCA) assay (Thermo) according to 
the manufacturer’s instructions. The samples pre- and 
post-loading and standards from 2 – 30 µg/mL IGF 
were measured with the bicinchoninic acid assay.  
We also used a Dylight 680-labled analogue of 
the IGF protein (IGF-680). This construct was pre-
pared by adding 100 µg of IGF to 50 µg (~16-fold 
molar ratio dye:IGF) of Dylight680-NHS ester for 1 
hour. The product was cleaned with size exclusion 
chromatography and confirmed by mass spectrome-
try. Release of IGF from the MSNs was monitored 
with fluorescence. Here, 1.5 mg of MSNs loaded with 
IGF-680 was placed in 500 µL of PBS. The sample was 
periodically centrifuged and the fluorescence of the 
supernatant measured to estimate release of the 
IGF-680 from the MSN.  
In Vivo Imaging. All animal work was con-
ducted in accordance with the Administrative Panel 
on Laboratory Animal Care at Stanford University. 
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MSNs were labeled at 250 µg/mL in media for 4 hours 
and then washed 3 times to remove unbound MSNs. 
The cells were then detached from the flask and 
counted. Cell pellets were resuspended in 100 µL of 
50:50 media:matrigel and implanted into the left ven-
tricle wall of nude mice under ultrasound guidance 
with a custom-made 30 gauge catheter. Imaging con-
ditions include a 40 MHz transducer at 300 frames per 
second.  
Statistical Analysis. Unless stated otherwise, all 
experiments use 3 replicates. Data means and stand-
ard deviation were computed in Microsoft Excel 2007. 
The standard error of measurement was calculated 
from the standard deviation and n (number of inde-
pendent trials). We used a two-tailed Student’s t test 
for significance and considered p values <0.05 to be 
significant. Limits of detection were calculated at 3 
standard deviations above the background mean.  
Results 
Our goal is a “theranostic” nanoparticle that in-
creases cell survival both through diagnostic imaging 
and therapeutic drug delivery (Fig. 1A). The ultra-
sound signal will allow intra-cardiac delivery away 
from fibrotic tissue, and the delivery of growth factors 
will increase cell survival after the trauma of ischemia 
and cell transplantation. Below we describe the syn-
thesis and characterization of theranostic MSNs, their 
utility in cell imaging, and their performance as drug 
delivery vehicles for IGF.  
Nanoparticle Characterization and Degrada-
tion. Our first step was to characterize the material. 
Fractions were dried to completeness and weighed to 
determine a working concentration of 22.1 ± 0.2 
mg/mL. We then diluted the material to an optical 
density of 0.1 and dried 2 µL on a formvar grid over-
night for TEM (Fig. 1B, C). We collected over 20 
fields-of-view with an average of 15 MSNs per image. 
The average size by TEM was 384 ± 134 nm (Fig. 1E). 
We used TEM and line profiling to study the pore size 
and found the pore size was 4.1 ± 1.1 nm (Fig. 1D), 
which agreed well with the manufacturer’s reported 
pore size. The EDS analysis showed obvious peaks 
from silicon and oxygen as well as small but charac-
teristic gadolinium peaks near 927, 6030, and 6730 
meV (Fig. 1F). Dynamic light scattering studies of 
freshly suspended particles had a peak near 2000 nm 
and PDI values over 0.6 indicating a lack of colloidal 
stability and agglomeration. After one hour of settling 
on the bench, we could obtain the data in Figure 1E 
with a peak at 255 nm and a PDI value of ~0.3. We 
used ICP and measured 3.1 x 106 Gd atoms per MSN. 
We estimated the average weight per MSN to be 2.2 x 
10-14 g by measuring the number of particles per 
volume with a Nanosight instrument and 
converting with the known mgs of MSN 
per volume, i.e. 22.1 mg/mL in stock con-
centration diluted 10,000-fold for Na-
nosight measurement. Using the 2.2 g/cm3 
density of silica, this average particle 
weight corresponds to a nanoparticle po-
rosity of approximately 50%.  
 
 
 
 
Figure 1. Experimental Design and Physical Charac-
terization. A) MSNs have impedance mismatch to backscatter 
ultrasound, MRI signal via Gd3+ and optical signal from fluo-
rescein. The same nanoparticles offer sustained release of IGF 
to increase MSC survival. B) TEM images show mesoporous 
particles with 4.1 nm pores (C) determined by line profiling (D). 
Red box in B indicates area imaged at higher magnification in C. 
Line in C is representative of profile used to construct D. Panel 
E is DLS data of the MSNs. Further characterization by EDS 
shows expected peaks for silicon and oxygen as well as gado-
linium from the secondary tag (F). Copper signal in F is from the 
TEM grid. Panel G is a histogram of MSN sizes from the TEM 
data in nm. 
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Figure 2. Biodegradation of the MSNs in vitro. A 200 mL sample of 0.22 mg/mL MSNs was exposed to dynamic 0.1X PBS and stirred in a sintered glass funnel 
(see Additional File 1: Fig. S2). The retentate was collected and imaged with TEM at the following time points: 30 minutes (A), 7 days (B), 12 days (C), 15 days (D), 
18 days (E), and 24 days (F). The MSNs appear to be degrading from the inside out with a hollow morphology appearing over time (B, C), which finally collapses upon 
itself (D, E). 
 
We next serially diluted the product and meas-
ured the ultrasound and MRI signaling capacity of the 
product (Additional File 1: Fig. S1). The calculated 
limit of detection via ultrasound is 1.2 µg/mL and 
15.6 µg/mL via MRI. This is 0.09 pM MSN by ultra-
sound and 1.2 pM by MRI. To assess whether any 
Gd3+ was dissociated from the MSNs and free in the 
solution, we also imaged the supernatant from 250 µL 
of 22.1 mg/mL of centrifuged MSNs. The MRI of the 
supernatant had T1-weighted signal identical to the 
water control. By ICP, the free Gd3+ in solution was 
400-fold lower than the MSN solution.  
The next goal was to understand nanoparticle 
degradation with an open dissolution system Addi-
tional File 1: Fig. S2A). We used ICP to measure Si 
and Gd in the eluate (Fig. S2B), and the retentate was 
studied with TEM (Fig. 2). The ICP data shows that 
the release of DOTA-chelated Gd is highest 48 hours 
after the beginning of the dissolution study, and the 
silicon has a maximum concentration 7 days into the 
study (Additional File 1: Fig. S2). To determine if the 
sintered glass funnel could be artificially inflating the 
Si concentration, we measured the Si concentration in 
buffer passed through the funnel, but with no MSNs. 
The average Si concentration in these samples was 
11.5 ± 2.7 ppm Si—more than 80-fold lower than the 
even the lowest sample concentration measured 
(0.927 ppm on day 22 of the study).  
We also recorded the volume of eluent at each 
time point and used the volume and concentration to 
calculate that the amount of Si present in all fractions 
was 8.38 mg of Si or 27.5 mg of SiO4-. This is 94.2% of 
the original 29.2 mg of sample that was added to the 
dissolution apparatus indicating nearly complete 
dissolution in 24 days and confirming the TEM data. 
As a control, we also studied the dissolution of Stöber 
nanoparticles. These materials show the same mor-
phology after 24 days of dissolution testing (Fig. S2D) 
as they did at day 0 (Fig. S2C). While these materials 
did initially release some small amounts of Si in dis-
solution, the Si values are 5- to 10-fold lower (Fig. 
S2B) that of MSNs. 
Nanoparticle Labeling, Fate, and Cytotoxicity. 
Next we studied the ability of the MSNs to label MSCs 
(Additional File 1: Fig. S3). We altered both the incu-
bation time and concentration and measured the up-
take with fluorescence. We noted a plateau in signal 
from 100 – 250 µg/mL indicating that further in-
creases did not result in higher signal and suggesting 
that no more nanoparticles could be loaded inside of 
the cells (Fig. S3A). Similarly, 4 hours of incubation 
time was found to be optimal—more than 4 hours did 
not increase loading levels, but at 24 and 48 hours the 
cell viability decreased 10% and 15%, respectively. 
Thus, 4 hours of incubation at 250 µg/mL MSNs was 
used for all subsequent labeling. Epifluorescence mi-
croscopy indicated that the particles were localized to 
the cells with <1% of the MSN signal on the tissue 
culture flask suggesting low non-specific binding 
(Fig. S3C). TEM of the labeled cells confirms their 
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localization in the cytosol (Fig. S4). We performed 
epifluoresence (Fig. 3D) and confocal (Fig. 3E and 
Additional File 2: Supplementary Video SV1) mi-
croscopy, which show punctate clusters of NPs on 
both the cell interior and periphery indicating endo-
somal uptake consistent with previous reports[36]. 
TEM imaging also illustrated the different locations 
within the MSC that the MSNs may be located (Figs. 
3F, G, H). MSNs are seen both in the cytosol (Fig. 3G) 
and cell surface (Fig. 3H). This remains true even after 
1 week of growth (Additional File 1: Fig. S4E). In-
creasing magnification with TEM clearly illustrates 
the MSN lattice inside the MSC (Fig. S4D). The mode 
size of endocytosed MSNs was 350 nm (Fig. S4F) 
similar to Fig. 1E. We dissolved MSCs labeled with 
MSNs in 10 M NaOH base and measured Si content to 
estimate 22,000 MSNs per MSCs. This volume is ~500 
µm3 of MSN or approximately 3% of a typical 30 µm 
MSC.  
With a defined labeling protocol in hand, we 
next tested the ability to image the cells with ultra-
sound and MRI. Cells labeled for 4 hours at 250 
µg/mL were washed and detached from the tissue 
culture flask. Increasing numbers of cells from 0 to 
700,000 were placed in replicate wells of a 384 well 
plate to serve as an imaging phantom. This was se-
lected because the volume of each well is 112 µL, 
which is similar to the 100 µL injection volumes used 
in vivo [3]. Cells were imaged with both ultrasound 
(Fig. 3A) and T1-weighted MRI (Fig. 3B). The data 
show a linear relationship between the number of 
cells and imaging signal, which is important for 
quantitative applications (Fig. 3C). The R2 value for 
MRI was 0.995. The ultrasound data show some plat-
eau effect perhaps due to shadowing at higher con-
centrations of cells [37], however the R2 values were 
0.97 and 0.98 at 16 and 40 MHz, respectively for 
counts at and below 350,000. The limits of detection 
were 9,200 for 40 MHz ultrasound, 15,000 for 16 MHz 
ultrasound, and 85,000 for MRI. 
These labeled cells were further studied to un-
derstand biodegradation inside of cells. MSCs labeled 
with the MSNs were imaged with TEM 1, 2, and 3 
weeks after labeling (Fig. 4). At one week, many 
MSNs are still present in the cells (Fig. 4A). This was 
confirmed with EDS data—all 9 of 9 spots imaged had 
a robust silicon peak (Fig. 4E). However, by 2 weeks, 
the MSNs had less organized structures (Fig. 4B). By 
week 3 no MSNs could be seen, except for some ex-
tremely collapsed structures (Fig. 4C). Although some 
spherical objects were noted, EDS analysis indicated 
only osmium from the staining protocol and thus 
were not MSNs (only 3 of 9 spots imaged with EDS 
had Si peaks above background).  
 
Figure 3. MSN-labeled MSCs. A) Coronal view of 40 MHz ultrasound imaging of decreasing number of MSN-labeled MSCs. Green boxes outline the boundaries 
of wells in the phantom. B) Transverse view from T1-weighted MRI of the same cell sample. Scale bar and intensity bar to the right of A apply to both panels. C) Dose 
response curves for increasing numbers of cells shows linear relationships at R2 >0.97 for both MRI and ultrasound (US). D) Epifluoresence microscopy with MSC 
nucleus in blue and MSNs fluorescently tagged in green. Punctate areas are seen indicating endosomal accumulation of MSNs. E) Confocal microscopy image indicating 
that the MSNs are located both on the cell periphery and interior. Panels F-H are three representative TEM images of MSCs labeled with MSNs. Note that the MSNs 
are located both on the cell periphery (F, H) and interior (G). Nuc: nucleus; Black arrows: MSNs. 
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Figure 4. Biodegradation of the MSNs. MSCs were labeled with MSNs and cultured for 1 (A), 2 (B), or 3 (C) weeks and then analyzed with TEM. A similar 
change in morphology is seen as the in vitro experiments including a hollowing from the inside out and finally a collapse (C). The smaller panels (Ai, Bi, and Ci) show 
digital magnification to highlight the nanoparticle degradation. Arrows indicate smaller fragments of MSNs. During this experiment, media from the adherent cells was 
collected periodically and measured for Si with ICP (D). The three washes after labeling show decreasing Si content as free MSNs are removed. The concentration 
peaks at day 2 and then gradually decreases to baseline near day 11. (E) The EDS data of areas with nanoparticles shows decreasing Si and O signal as a function of 
time. Scale bars in A-C represent 250 nm, and those in Ai-Ci are 125 nm. Error bars in D represent the standard deviation of 3 replicates (up to day 7) and 2 replicates 
(days 9-14). 
 
We also measured the amount of Si in the media 
at various time points (Fig. 4D), and this data again 
confirms that the MSNs were biodegrading intracel-
lularly. During the washes, the concentration goes 
from nearly 100 ppm to 1 ppm. Interestingly, by day 2, 
this increases nearly 20-fold. This suggests degrada-
tion even inside of the cells with release of the silicic 
acid monomers into the media and not residual free 
MSNs from the labeling protocol. This concentration 
then continues to drop until approaches the back-
ground levels (<0.001 ppm Si) in fresh cell culture 
media (no MSNs).  
The next goal was to determine whether cyto-
toxic effects were produced by labeling the cells with 
the MSNs. We used a variety of chemical tools to 
measure the cells’ metabolism, viability, oxidative 
stress, and inflammatory status. We measured the 
effect of mitochondrial reductase (a well-known 
marker of cell metabolism) with both MTS (Fig. 5A) 
and resazurin (Fig. 5B)—both assays indicated no 
effect on cell metabolism. For MTS, the 500 μg/mL 
concentration of MSNs did show a 10% decrease, but 
it was not significant (p = 0.07). There was no statis-
tically significant change even at levels up to 1000 
μg/mL, the positive control of CTAB was 70% lower 
however and validated the assay. The endpoint of the 
MTS assay is an absorbance measurement, and we 
were concerned that absorbance from nanoparticles 
inside of the cells could artificially contribute to the 
optical density. Thus, we removed the media from all 
wells and plated it in a fresh plate. While the absolute 
value of the OD did decrease for all wells, the toxicity 
trends remained the same.  
The release of ATP is another marker of cell 
count and viability and decreased ATP levels can 
correspond to toxicity [38]. An ATP assay using lu-
ciferase shows little change due to MSNs. The con-
centration decreased 25% due to treatment with eth-
anol as a positive control and actually increased 17% 
at 1000 μg/mL of MSNs (Fig. 5A). Additional assays 
such as the EthD-III assay showed no significant in-
crease in cell signal versus baseline, except the posi-
tive control (34% increase) and the 500 μg/mL sample 
(64% increase; Fig. 5B). Measurement of ROS indi-
cated that levels increased at a MSN concentration of 
1000 µg/mL (Fig. 5C). Finally, we measured whether 
the presence of MSNs affected the growth kinetics of 
MSCs (Fig. 5D). Control cells and cells labeled with 
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MSNs at 250 µg/mL were plated at 1000 cells/cm2 
and monitored daily. There was no significant 
(p>0.05) change in their doubling time—2.46 days for 
unlabeled cells and 2.48 days for labeled cells. We also 
studied cells that had been labeled with MSNs 5 days 
prior to see if there was any delayed effects (Fig. 5D, 
Pos*). The doubling time of this population was again 
unchanged at 2.57 days. 
Pro-survival Agent Loading and Utilization. 
Although IGF has been shown to promote cell sur-
vival in vivo[8, 33, 34], we briefly confirmed this observa-
tion here. To simulate necrotic regions within the 
heart, cells were grown in incomplete media, i.e., cell 
culture media with no fetal bovine serum or 
L-glutamine. This media was supplemented with in-
creasing concentrations of IGF as a pro-survival fac-
tor. After 5 hours, we noted 25% increased viability in 
the cells grown with 200 ng/mL IGF (Fig. 6A). Next, 
we characterized the ability of the MSNs to incorpo-
rate IGF. To estimate the amount of IGF loaded into 
the MSNs we used a BCA assay. For samples with a 
starting concentration of 23.0 µg/mL IGF, the final 
concentration after 4 h incubation in samples without 
MSNs was 18.4 ± 1.2 µg/mL IGF and in samples with 
MSNs was 12.5 ± 0.1 µg/mL. This decrease was sig-
nificant at p<0.01. Considering the reaction volume 
and 7.6 kDa molecular weight of IGF, this difference is 
1.1 x 1014 IGF proteins loaded on the 3.2 mg of MSNs 
or 750 IGF proteins per MSN (500 µg protein/g MSN). 
To monitor release of the IGF, we used a fluo-
rescently tagged IGF and monitored its release into 
solution (Fig. 6B). In this experiment, we washed the 
nanoparticles three times after loading. The fluores-
cence of the third wash was 103 ± 13 a.u. Three hours 
later, this value increased to 202 ± 16 a.u. This indi-
cates that IGF was diffusing out of the MSN pores and 
was not a result of incomplete washing. The IGF sig-
nal remained significantly (p<0.05) elevated during 
successive buffer exchanges for up to 48 hours (Fig. 
6B).  
We next plated cells at 5000 cells/cm2 and used 
the theranostic MSNs with MSCs and measured cell 
proliferation with a MTS assay over multiple days 
(Fig. 6C). Cells grown in complete media (CM) had 
viability that was 30-50% higher than those grown in 
serum free incomplete media (ICM). The difference 
between the complete media and incomplete media 
was significant at p<0.01. MSCs grown in media sup-
plemented with free IGF (no MSNs) for 24 hours had 
viability that was 10% lower than complete media, but 
10% higher than incomplete media. These differences 
were not significant (p>0.05). To test whether metab-
olism of the IGF protein was the mechanism of action, 
we also studied the proliferative effect of 200 ng/mL 
BSA—it had no statistically significant effect. This 
suggested that the IGF specifically encouraged cell 
survival, however this effect was short lived.  
 
Figure 5. Cytotoxicity data. Increasing concentrations of particles were used to label MSCs for 4 hours followed by treatment with different markers of cyto-
toxicity. All experiments were validated with a positive control (POS). A) The MTS reagent measures cell metabolism and showed no decrease at any concentration 
studied. A luciferase assay indicates that ATP production increased 17% at 1000 µg/mL, but this does not indicate toxicity. B) The resazurin (Alamar Blue) assay 
showed no decrease in cell cellular metabolism at any concentration, however the EthD-III viability marker indicated an increase in apoptosis at 500 µg/mL. C) The 
DCFH-DA assay showed increased ROS generation in the hydrogen peroxide positive control and 1000 µg/mL concentration. D) The proliferation assay monitored 
growth of naïve cells (Neg), cells labeled with 250 µg/mL MSNs 4 hour prior (POS), and cells labeled with 250 µg/mL MSNs 5 days prior (Pos*). We found no change 
in the proliferation rate across these three samples. Error bars in all panels represent the standard deviation of at least 4 replicates.  
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Figure 6. Pro-Survival Agents. A) The ability of IGF to increase cell survival under serum-free conditions was studied at increasing concentrations of IGF—values 
of 200 ng/mL were optimal and significantly (p<0.001) increased viability 25% relative to untreated cells. B) The release kinetics of IGF from the MSNs showed 
sustained release up to 48 hours. Here red triangles are the percent of total release (right axis) and the black diamonds are absolute fluorescence from free IGF. C) 
Sustained release of (IGF) from porous MSNs increases cell survival under serum-free media challenge as studied with MTS assay. The * indicates that the IGF-NPs 
had a statistically significant increase in viability versus incomplete media (p<0.05) and free IGF (p<0.05). IGF: Free IGF; BSA: Bovine Serum Albumin Control; 
MSN/IGF: MSNs loaded with IGF; ICM: Incomplete Media (serum-free); CM: Complete Media. Error bars represent the standard error.  
 
By day 2, the IGF-NPs had a statistically signifi-
cant increase in viability compared to incomplete 
media (p<0.05) and compared to free IGF (p<0.05). 
After one week of incubation in serum-free media, the 
MSCs with theranostic MSNs have viability that is 
40% higher than MSCs grown in complete media 
(p<0.05). Other important controls included cells with 
MSNs only (no IGF). They had viability values similar 
to those in the incomplete media and suggested that 
there was no chemical interference with the MTS as-
say that may have artificially increased the MSN-IGF 
signal. A positive control that killed the cells with 
CTAB also validated the assay.  
In a final study, we injected nude mice with 
MSN-labeled MSCs or vehicle control (Fig. 7; Addi-
tional File 3: Supplementary Video SV2). We noted a 
2-fold increase in backscatter after implanting 500,000 
MSCs and a 1.2-fold increase in backscatter after im-
planting vehicle only. The increase from the MSCs is 
due to their MSN label and the trauma of implant 
causes the 20% increase in backscatter from the vehi-
cle. We estimated cell counts down to 100,000 should 
be detectable based on 3 standard deviations above 
the background.  
Discussion 
Our goal was to deploy the established utility of 
MSNs in both imaging and drug delivery to cardiac 
stem cell therapy (Fig. 1). Indeed, silica[39-41] and 
silicon-based[42, 43] mesoporous nanoparticles offer 
sustained release of drug in close proximity to the 
cells at high local concentrations with less off-site ef-
fects[44] and can markedly increase cell survival[45]. 
A further advantage of these designs is that imaging 
can be done through multimodal approaches includ-
ing MRI [43, 46], optical, ultrasound [17, 19, 20] as 
well as multimodality approaches such as opti-
cal/PET [47], optical/MRI [48, 49], and ultra-
sound/gamma imaging [18]. Although MSNs can be 
made with a variety of aspect ratios [40, 50, 51] and 
pores sizes [52], we selected commercially available 
materials with 4 nm pore size because this dimension 
was well matched to IGF’s hydrated radius of 3.5 nm 
[53]. The 350 nm size has been shown to backscatter 
ultrasound waves [16, 17]. These nanoparticles are not 
as monodisperse as gold nanoparticles or as colloi-
dally stable as quantum dots, but these features con-
tribute to their ultrasound echogenicity. We previ-
ously showed that agglomeration inside the cell actu-
ally increased the ultrasound backscatter [16]. Col-
loidal stability would be a much more important con-
sideration if these particles were being injected intra-
venously, but because cell labeling is done ex vitro 
follow by in vivo implantation we are less concerned 
about the poor colloidal stability. 
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Figure 7. In vivo Implantation of MSN-Labeled MSCs. Panels A and C are pre-injection and panels B and D are post-injection of either vehicle (B) or 500,000 
MSCs (D) into the left ventricle wall of nude mice. The red circle indicates the area of implantation and the increased echogenicity in D verus the pre-injection panel 
is clear. No such signal increase occurs for the control in B. Scale bar represents 2 mm. LV: Left Ventricle.  
 
One consideration of using nanoparticles for 
drug delivery is clearance of the carrier from the 
body. Poly-lactic-co-glycolic acid and polyethylene 
glycol have established utility in drug delivery and 
renal clearance, but their impedance mismatch is in-
sufficient to generate ultrasound signal. While silica 
sol-gel nanoparticles <10 nm can clear via urinary 
excretion [54], the sizes needed for ultrasound signal 
(>50 nm) are limited by long-term accumulation in the 
reticuloendothelial system. In contrast, we were 
happy to find that MSNs had both good ultra-
sound/MRI signaling capabilities and straightfor-
ward degradation both in vitro (Fig. 2) and inside 
MSCs (Fig. 4).  
It was interesting that the nanoparticles seemed 
to degrade from the inside out. We noted a hollowing 
of the MSN after one week (Fig. 2B), and collapse of 
this shell during the third week of in vitro study (Fig. 
2C, D). A similar pattern was noted with cells (Fig. 
4C). This may be because lower solubility hydroxides 
form on the exterior of the MSN or re-precipitation of 
the silicic monomers. This may also be due to a denser 
amount of silica on the MSN surface as has been 
shown for aerosol generated nanoparticles [55]. Re-
gardless, more study is needed to completely under-
stand this observation. The 0.5 mL/min flow rate of 
PBS that the MSNs experienced during the in vitro 
experiments is a higher rate of aqueous exchange than 
the MSNs will experience in the intracellular envi-
ronment, and this flow rate may have a significant 
effect on the rate of dissolution. Nevertheless, we still 
observed nearly complete degradation of these parti-
cles by one month in cells (Fig. 4). The degradation 
time is important because exogenous contrast agents 
must be stable enough to complete their imaging task, 
but not so stable that they are never cleared from the 
body. However, it is rare for cell tracking experiments 
to proceed beyond the 3-4 weeks demonstrated here. 
We could also use combination of mesoporous and 
Stober particles to fine tune the ultrasound imaging 
window. 
Despite the fact that silica nanoparticles are al-
ready being used in humans [47] (clinicaltrials.gov 
NCT02106598), we wanted to confirm that the deg-
radation products did not have any adverse effects. 
We studied the proliferation of cells labeled with 
MSNs. During the first 5 days of growth—when silicic 
acid concentration is the highest (Additional File 1: 
Fig. S2B)—there was no change in cell proliferation 
(Fig. 5D).  
Labeling with 250 µg/mL MSNs offered both 
good ultrasound/MRI signal (Fig. 3) and no observa-
ble cytotoxicity (Fig. 5). At 250 µg/mL there was no 
decrease in metabolic activity (MTS and ATP assays) 
or increase in apoptosis (EthD-III) or ROS. At 500 
µg/mL apoptosis increased 60% above control cells. 
We also noted increased generation of ROS at 1000 
µg/mL via DCFH-DA. This concurs with a previous 
report that showed upregulated ROS generation at 1 
mg/mL, but not 0.2 mg/mL of MSNs [56]. However, 
the 250 µg/mL concentration showed no toxicity and 
stem cell imaging with cell counts below 10,000 were 
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achieved for ultrasound and below 100,000 for MRI. 
While this approach does not offer the single cell 
counting offered by micron-sized iron oxide particles 
and T2-weighted MRI[57], the detection limits are 
certainly suitable for the millions or tens of millions of 
cells used in human trials[2, 58]. These detection lim-
its could also facilitate a strategy in which only a 
percentage of the cells are labeled.  
The MSNs are located both on and inside the 
stem cells (Fig. 4 and S4) and thus can deliver IGF to 
the cell surface membrane where IGF receptors are 
located. We first validated the ability MSNs to se-
quester and offer sustained release of IGF. We noted 
release for up to 2 days, which is when 80% of MSCs 
have been shown to die in vivo [59]. Thus, this delivery 
may window may have important implications in 
prevent cell death in the left ventricle wall. Although 
MSCs with IGF-MSNs in serum-free media still had 
lower cell viability than those grown in complete me-
dia (Fig. 6), they were significantly (p<0.05) more vi-
able than MSCs grow in serum-free media with free 
IGF. This suggests that the MSNs offer sustained re-
lease of IGF to promote cell survival even under se-
rum-free conditions. This may have utility in human 
trials in which cells are implanted into necrotic and 
hypoxic regions of the heart. One question that is still 
unresolved is whether this approach will lead to 
greater cell survival in damaged myocardium in vivo. 
We are currently developing stem cells with stable 
reporter genes to answer this question.  
Conclusion 
We report a biodegradable MSN with ultra-
sound and MR imaging capabilities and have used it 
as a theranostic tool with mesenchymal stem cells. 
Key findings include: a) cell counting below 10,000 
with no measureable cytotoxicity at labeling concen-
trations of 250 µg/mL, b) biodegradation within cells 
in under one month, and c) a 40% increase (p<0.05) in 
cell viability under serum-free conditions. By offering 
sustained release of IGF to MSCs, the MSNs may en-
courage cell survival despite transplantation into hy-
poxic or necrotic regions of the heart. One limitation 
of this work is that it is not a true marker of cell via-
bility. That is, the MSN is always producing signal 
regardless of whether the cells is alive or dead. While 
not unique to MSN nanoparticle imaging agents, and 
this shortfall could be counteracted by systematically 
studying cells with both a nanoparticle imaging agent 
and a reporter gene [60]. Future work will evaluate 
alternative pro-survival agents such as pinacidil and 
evaluate the utility of this approach in animal models 
of human disease.  
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